Results 1 to 10 of about 16,167 (200)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]

Endocrine and Metabolic Science
Chronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe, Arden B. Piepho, Chetan K. Gomatam, Peyton Debell, Megan N. Ballinger, Jill A. Rafael-Fortney   +5 more
doaj   +4 more sources

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]

Pharmaceuticals, 2021
Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore,
Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs   +5 more
doaj   +8 more sources

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists [PDF]

Reviews in Cardiovascular Medicine
Cardiovascular (CV)-kidney-metabolic (CKM) syndrome is a complex disorder characterized by the co-occurrence of CV risk factors, including chronic kidney disease (CKD), hypertension, and metabolic dysfunction, which creates a vicious cycle where one ...
Biykem Bozkurt, James L. Januzzi, Shweta Bansal   +2 more
doaj   +2 more sources

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES? [PDF]

Frontiers in Cardiovascular Medicine, 2015
Despite the availability of anti-hypertensive medications with increasing efficacy up to 50% of hypertensive patients have blood pressure levels (BP) not at the goals set by international societies.
Giuseppe eMaiolino, Matteo eAzzolini, Gian Paolo eRossi   +2 more
doaj   +2 more sources

Mineralocorticoid receptor antagonists promote renal immunosenescence. [PDF]

Int Urol Nephrol
Abstract Chronic kidney disease (CKD) is often associated with chronic inflammation, influenced by the activation of mineralocorticoid receptors (MR). This review focuses on changes in immune cells and explores the important role that MR antagonists (MRAs), especially the new nonsteroidal MRA, finerenone, play in alleviating renal and
Wang QR, Yang Y.
europepmc   +3 more sources

Mineralocorticoid receptor antagonists in cardiovascular translational biology. [PDF]

Cardiovasc Endocrinol Metab, 2023
This review examines the role of mineralocorticoid receptor antagonists (MRAs) in cardiovascular biology and the molecular mechanisms involved in mineralocorticoid receptor antagonism. The data discussed suggest that MRAs can play an important role in decreasing the impact of inflammation and fibrosis on cardiorenal outcomes.
Chilton RJ, Silva-Cardoso J.
europepmc   +3 more sources

Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists. [PDF]

Diabetologia, 2023
AbstractThe overactivation of the mineralocorticoid receptor (MR) promotes pathophysiological processes related to multiple physiological systems, including the heart, vasculature, adipose tissue and kidneys. The inhibition of the MR with classical MR antagonists (MRA) has successfully improved outcomes most evidently in heart failure.
Savarese G, Lindberg F, Filippatos G, Butler J, Anker SD.   +4 more
europepmc   +6 more sources

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis [PDF]

Frontiers in Cardiovascular Medicine
BackgroundMineralocorticoid receptor over-activation drives maladaptive myocardial fibrosis, vascular inflammation and renal sodium retention across the entire spectrum of left ventricular ejection fraction (LVEF).
Yue Zhang, Yin-Chao Bao, Li-Xia Wang, Hong-Juan Zhao, Jing Sun, Lin Sun, Wei Duan, Ming Du, Lei-Jun Wang, Qin-Yan An, Wen-Ze Yang   +10 more
doaj   +2 more sources

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

Vascular Health and Risk Management, 2017
Juan Carlos Yugar-Toledo,1 Rodrigo Modolo,2 Ana Paula de Faria,2 Heitor Moreno2 1São José do Rio Preto Medicine School – FAMERP, São José do Rio Preto, 2School of Medical Sciences, University of Campinas (UNICAMP ...
Yugar-Toledo JC, Modolo R, de Faria AP, Moreno H   +3 more
doaj   +4 more sources

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease [PDF]

Frontiers in Pharmacology
Every year millions die prematurely of complications related to chronic kidney disease (CKD). Main causes of death are connected with cardiovascular (CV) complications.
Mai Rosenberg, Alexei Y. Bagrov
doaj   +2 more sources